News

IDegLira is a once-daily, single injection fixed combination of insulin degludec (Tresiba) and liraglutide (Victoza) for the treatment of adults with type 2 diabetes. Based on the data

In addition, Lilly could launch an average of two new indications or line extensions for already-approved products per year during that same time period. "We’re pleased to share

Headline results from the 2,802-patient Salford Lung Study (SLS) in COPD showed that the inhaled therapy achieved a superior reduction in exacerbations versus usual care – which included

A total 115 patients were enrolled in the placebo-controlled, randomized, double-blind trial, which evaluated the efficacy and safety of three separate, twice-daily, dosing regimens of Prurisol — 50

Invokamet is a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet. The drug has now been approved as a first-line treatment for adults with type

This presents the possibility of completing the clinical development program with only one pivotal efficacy study in each of the two indications being focused on by Isofol (colorectal

It is the first application filed in the US by Samsung Bioepis as part of its alliance with Merck to provide biosimilar alternatives to existing biologic medicines. Samsung

Andrew Lees, MD FRCP, FMedSci, Professor of Neurology, (The National Hospital for Neurology and Neurosurgery, Queen Square and Emeritus Director, Reta Lila, Weston Institute of Neurological Studies, University

The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for cabozantinib compared with sunitinib in patients with advanced intermediate-